KREBSBEHANDLUNG

European patent · EP3576740 · In force

Register entry

Publication number
EP3576740
Application number
EP18702299
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Feb 2, 2018
Published
Dec 11, 2019
Granted
Jun 14, 2023
Protection ends at the latest
Feb 1, 2038
Next annual fee due
Feb 28, 2027
IPC classes
A61K 31/498 (2006.01)
G01N 33/574 (2006.01)
A61P 35/00 (2006.01)
Priority
US 201762455211 P 06.02.2017
EP 17209098 20.12.2017
PCT application
PCT/EP2018/052694 02.02.2018
PCT publication
WO2018/141921 09.08.2018
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Mar 1, 2026

    Change

    Published in Swissreg on 01.03.2026

  2. Mar 1, 2025

    Change

    Published in Swissreg on 01.03.2025

  3. Apr 24, 2024

    Change

    Published in Swissreg on 24.04.2024

  4. Mar 1, 2024

    Change

    Published in Swissreg on 01.03.2024

  5. Jun 21, 2023

    Agent entered

    Representative
    Novagraaf International SA, Chemin de l'Echo 3, 1213 Onex

    Published in Swissreg on 21.06.2023

  6. Jun 14, 2023

    Granted

    Published in Swissreg on 14.06.2023

Parties

Holder

Janssen Pharmaceutica NV

Turnhoutseweg 30, 2340 Beerse, BE

Agent

Novagraaf International SA

Chemin de l'Echo 3, 1213 Onex

Inventor

LORIOT, Yohann

94805 Villejuif Cedex, FR

AVADHANI, Anjali, Narayan

Springhouse Pennsylvania 19477, US

STUYCKENS, Kim

2340 Beerse, BE

DE PORRE, Peter, Marie, Z.

2340 Beerse, BE

PEREZ RUIXO, Juan, Jose

28042 Madrid, ES

SIEFKER-RADTKE, Arlene, O.

2340 Beerse, BE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.